Session » Patient Outcomes, Preferences, & Attitudes Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1236

A Novel Role for Artificial Intelligence in Detecting Distinctive Scleroderma Facial Features

10:30AM-12:30PM: Abstract Number: 1243

A Patient-Focused Program for Using Steroids Wisely

10:30AM-12:30PM: Abstract Number: 1244

Creation of a New Patient-reported Outcome for a Combined Response Index for Limited Cutaneous SSc Using the FDA Guidance on Patient Reported Outcome Measures: The CRISTAL PRO

10:30AM-12:30PM: Abstract Number: 1251

Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives

10:30AM-12:30PM: Abstract Number: 1255

Development and Validation of a Brief Measure of Uncertainty Among Patients with Vasculitis and Other Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1239

Innovative Patient Empowerment: Evaluating the Effect of a Physician-created Educational Video and To-do Lists on Promoting Preventive Health Measures in Rheumatic Disease Patients

10:30AM-12:30PM: Abstract Number: 1245

Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative

10:30AM-12:30PM: Abstract Number: 1240

Living with Antiphospholipid Antibodies: A Photovoice Exploration

10:30AM-12:30PM: Abstract Number: 1246

Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies

10:30AM-12:30PM: Abstract Number: 1248

Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis

10:30AM-12:30PM: Abstract Number: 1233

Narrative Medicine Intervention for Mental Wellbeing in Juvenile Myositis and Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 1241

Optimizing Communication of Methotrexate (MTX) Side Effects: A Patient-Centered Approach Focused on Learning Styles and Preferred Language

10:30AM-12:30PM: Abstract Number: 1234

Patient and Physician Preferences for Pain Relief Treatment for Moderate-to-Severe Pain Associated with Knee Osteoarthritis: A Qualitative Exploration

10:30AM-12:30PM: Abstract Number: 1232

Patient Reported Impact of Psoriatic Arthritis and Desired Treatment Outcomes

10:30AM-12:30PM: Abstract Number: 1249

Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry

10:30AM-12:30PM: Abstract Number: 1253

Patterns of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus with or Without Concurrent Fibromyalgia

10:30AM-12:30PM: Abstract Number: 1247

Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren’s Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations

10:30AM-12:30PM: Abstract Number: 1242

Qualitative Patient Interview Study in Patients with Systemic Lupus Erythematosus to Assess Patient Perception of Fatigue and Skin-Related Symptoms

10:30AM-12:30PM: Abstract Number: 1250

Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 1235

Rheum to Grow: Supporting Young Adults with Childhood-Onset Rheumatic Disease in Their Transition to Adult Care

10:30AM-12:30PM: Abstract Number: 1252

Rheuminating About Drugs, Sex, and Alcohol? Assessing the Informational Needs of Adolescents and Young Adults with Rheumatic Disease

10:30AM-12:30PM: Abstract Number: 1238

Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in Those with Polymyalgia Rheumatica

10:30AM-12:30PM: Abstract Number: 1237

The Art of Choosing Together: Unveiling the Patient’s Perspective in Rheumatology

10:30AM-12:30PM: Abstract Number: 1254

The Impact of Eosinophilic Granulomatosis with Polyangiitis on the Health-Related Quality of Life of Patients and Their Ability to Work: Evidence from a Real-World Survey in Clinical Practice

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].